Ergoren Mahmut Cerkez, Paolacci Stefano, Manara Elena, Dautaj Astrit, Dhuli Kristjana, Anpilogov Kyrylo, Camilleri Giorgio, Suer Huseyin Kaya, Sayan Murat, Tuncel Gulten, Sultanoglu Nazife, Farronato Marco, Tartaglia Gianluca Martino, Dundar Munis, Farronato Giampietro, Gunsel Irfan Suat, Bertelli Matteo, Sanlidag Tamer
Department of Medical Biology, Faculty of Medicine, Near East University, Nicosia, Cyprus; DESAM Institute, Near East University, Nicosia, Cyprus.
MAGI'S LAB.
Acta Biomed. 2020 Nov 9;91(13-S):e2020022. doi: 10.23750/abm.v91i13-S.10817.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current pandemics. This virus attacks the cells by binding to the transmembrane angiotensin I converting enzyme 2. In this study, we experimented a food supplement containing alpha-cyclodextrin and hydroxytyrosol for the improvement of the defenses against the SARS-CoV-2. Hydroxytyrosol has anti-viral properties and is able to reduce the serum lipids in mice. α-cyclodextrin has the ability to deplete sphingolipids and phospholipids from the cellular membranes. The aim of the present preliminary open non-controlled interventional study was to evaluate the efficacy of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2.
Fifty healthy volunteers at a higher risk of SARS-CoV-2 infection from Northern Cyprus and six positive individuals for SARS-CoV-2 were enrolled in this study. The in silico prediction was performed using D3DOCKING to evaluate the interactions of hydroxytyrosol and alpha-cyclodextrin with proteins involved in the SARS-CoV-2 endocytosis.
The 50 volunteers did not become positive in 15 days for SARS-CoV-2 after the administration of the compound for two weeks, despite they were at higher risk of infection than the general population. Interestingly, in the cohort of six positive patients, two patients were administered the spray and became negative after five days, despite the viral load was higher in the treated subjects than the untreated patients who became negative after ten days. In addition, we identified possible interactions among hydroxytyrosol and alpha-cyclodextrin with the protein Spike and the human proteins ACE2 and TMPRSS2.
We reported on the results of the possible role of alpha-cyclodextrin and hydroxytyrosol in improving defenses against SARS-CoV-2. The next step will be the administration of the compound to a larger cohort in a controlled study to confirm the reduction of the infection rate of SARS-CoV-2 in the treated subjects.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是当前大流行的病原体。这种病毒通过与跨膜血管紧张素I转换酶2结合来攻击细胞。在本研究中，我们试验了一种含有α-环糊精和羟基酪醇的食品补充剂，以提高对SARS-CoV-2的防御能力。羟基酪醇具有抗病毒特性，并且能够降低小鼠的血脂。α-环糊精能够从细胞膜中消耗鞘脂和磷脂。本项初步开放性非对照干预研究的目的是评估α-环糊精和羟基酪醇在提高对SARS-CoV-2防御能力方面的功效。
招募了50名来自北塞浦路斯的SARS-CoV-2感染风险较高的健康志愿者以及6名SARS-CoV-2阳性个体参与本研究。使用D3DOCKING进行计算机模拟预测，以评估羟基酪醇和α-环糊精与参与SARS-CoV-2内吞作用的蛋白质之间的相互作用。
50名志愿者在服用该化合物两周后，15天内SARS-CoV-2检测未呈阳性，尽管他们的感染风险高于普通人群。有趣的是，在6名阳性患者队列中，两名患者使用喷雾后5天转为阴性，尽管治疗组患者的病毒载量高于未治疗组患者，后者10天后才转为阴性。此外，我们确定了羟基酪醇和α-环糊精与刺突蛋白以及人类蛋白ACE2和TMPRSS2之间可能存在的相互作用。
我们报告了α-环糊精和羟基酪醇在提高对SARS-CoV-2防御能力方面可能发挥的作用的结果。下一步将在对照研究中对更大的队列使用该化合物，以确认治疗组中SARS-CoV-2感染率的降低情况。
